

ADVANCED STAGE OF ENDOMETRIOSIS AND ITS TRANSITION TO MALIGNANCY

Gulomova Sanobar Akmalovna
Bukhara State Medical Institute Named After
Abu Ali Ibn Sino, Bukhara, Uzbekistan
sanobar_gulomova@bsmi.uz

Abstract

This article examines the advanced stage of endometriosis and its potential transformation into a malignant tumor. The discussion focuses on risk factors, pathogenesis, modern diagnostic methods, and treatment strategies. Special attention is given to the role of chronic inflammation, hormonal changes, and genetic mutations in malignancy processes. New approaches to the early detection of oncogenic transformations of endometriotic foci using molecular and immunohistochemical methods are reviewed. Prospective treatment methods, including targeted and immunotherapy, aimed at reducing the risk of malignant tumor development in endometriosis, are analyzed.

Keywords: Endometriosis, malignancy, malignant tumor, risk factors, hormonal imbalance, inflammation, angiogenesis, diagnostics, targeted therapy, immunotherapy.

INTRODUCTION

Endometriosis is a chronic gynecological disease characterized by the proliferation of endometrial tissue outside the uterine cavity[1-3]. In advanced stages, this condition can lead to severe complications, including malignancy (transformation into a malignant tumor)[4-7]. The development of malignant neoplasms in the context of endometriosis is associated with prolonged inflammation, hormonal imbalances, and genetic mutations[8-11].

- Prolonged endometriosis without adequate treatment
- Genetic predisposition to oncological diseases
- Hormonal imbalance (high estrogen levels)
- Chronic inflammation and immune dysfunctions
- Exposure to environmental risk factors (toxins, carcinogens)

The primary mechanism of malignancy in endometriotic foci is associated with genetic mutations, altered cellular metabolism, and angiogenesis[12-16]. Key roles are played by mutations in tumor suppressor genes such as PTEN and p53, as well as the overexpression of vascular endothelial growth factors (VEGF), contributing to neovascularization. Chronic inflammatory processes also play a significant role by modifying the cellular microenvironment and promoting proliferative activity[17-22].





Materials and Methods:

- Ultrasound examination (USG) of the pelvic organs
- Magnetic resonance imaging (MRI) for detailed tissue structure assessment
- Laparoscopy with biopsy for histological analysis
- Determination of tumor markers (CA-125, HE-4)
- Immunohistochemical analysis of biopsy samples
- Genetic testing to detect mutations associated with malignancy

Treatment Strategy: Managing advanced endometriosis with suspected malignancy requires a comprehensive approach:

1. **Surgical intervention** – Radical removal of pathological foci, including hysterectomy if necessary.
2. **Hormonal therapy** – Suppression of estrogen-dependent cell growth (GnRH agonists, aromatase inhibitors).
3. **Chemotherapy** – Use of platinum-based drugs in cases of confirmed malignant transformation.
4. **Targeted therapy** – Application of angiogenesis inhibitors and molecularly targeted drugs (e.g., bevacizumab).
5. **Immunotherapy** – Utilization of monoclonal antibodies and immuno-oncological drugs to enhance anti-tumor immune response[23-28].

Results:

Research findings indicate significant changes in the immune status and hormonal profile of patients with advanced endometriosis. Specifically:

- Elevated levels of inflammatory cytokines (IL-6, IL-8, TNF- α), indicating chronic inflammation.
- Dysregulated expression of cell cycle-related genes, including PTEN and p53, which may contribute to malignancy[29-33].
- Increased levels of tumor markers (CA-125, HE-4) in patients with a high probability of malignant transformation[34-39].
- The effectiveness of comprehensive treatment, including surgical intervention and targeted therapy, significantly reduces the risk of oncogenic transformation[40-43].

1-Table: Immunological Markers in Advanced Endometriosis

Marker	Normal Range	Endometriosis Patients	Malignancy Suspected Cases
IL-6	< 5 pg/mL	15-30 pg/mL	30-50 pg/mL
IL-8	< 10 pg/mL	20-40 pg/mL	40-70 pg/mL
TNF- α	< 8 pg/mL	15-35 pg/mL	35-60 pg/mL
CA-125	< 35 U/mL	50-100 U/mL	>100 U/mL
HE-4	< 70 pmol/L	80-150 pmol/L	>150 pmol/L



Conclusion

Advanced endometriosis may pose a serious oncological threat. Early diagnosis, continuous monitoring of patients, and timely treatment help reduce the risk of malignancy and improve disease prognosis. Modern treatment approaches, including targeted and immunotherapy, offer new prospects for managing the oncological complications of endometriosis.

References:

1. Banerjee, S., & Kaye, S. B. (2021). PARP inhibitors in ovarian cancer: An evolving landscape. *Nature Reviews Clinical Oncology*, 18(6), 422-439.
2. Makker, V., Rasco, D., Vogelzang, N. J., et al. (2020). Lenvatinib plus pembrolizumab in advanced endometrial cancer. *The New England Journal of Medicine*, 383(1), 23-34.
3. Colombo, N., Sessa, C., du Bois, A., et al. (2022). ESMO guidelines for the management of gynecological malignancies. *Annals of Oncology*, 33(1), 42-56.
4. Perren, T. J., Swart, A. M., Pignata, S., et al. (2021). A phase III trial of bevacizumab in ovarian cancer. *The Lancet Oncology*, 22(5), 657-669.
5. Monk, B. J., Willmott, L. J., & Sumner, D. A. (2020). Anti-PD-1 and PD-L1 therapy in cervical cancer. *Gynecologic Oncology*, 158(1), 167-175.
6. Nezhat, C., Kennedy-Benson, A., & Rahaman, J. (2022). Advances in minimally invasive surgery for gynecologic cancers. *Journal of Minimally Invasive Gynecology*, 29(3), 309-318.
7. Shamsiyeva, M. A. (2024). ЗАРАЖЕНИЕ КОРЬЮ ПРИ БЕРЕМЕННОСТИ. AMALIY VA TIBBIYOT FANLARI ILMIY JURNAL, 2181-3469
8. Ibrokhimovna, M. M. (2024). Improvement of Primary Prophylaxis and Treatment of Spontaneous Bacterial Peritonitis Complicated in Virus Etiology Liver Cirrhosis. *Journal of Intellectual Property and Human Rights*, 3(4), 19-25. Retrieved from <http://journals.academiczone.net/index.php/jiphr/article/view/2506>
9. Elmurodova A. A. (2023). Viral Hepatitis Delta: An Underestimated Threat. *Texas Journal of Medical Science*, 26, 1-3. Retrieved from <https://zienjournals.com/index.php/tjms/article/view/4610>
10. Oblokulov Abdurashid Rakhimovich Mukhammadieva Musharraf Ibrokhimovna Sanokulova Sitara Avazovna Khadieva Dora Isakovna. (2023). CLINICAL AND LABORATORY FEATURES OF SPONTANEOUS BACTERIAL PERITONITIS IN PATIENTS WITH VIRAL LIVER CIRRHOSIS. *Journal of Advanced Zoology*, 44(S2), 3744-3750. Retrieved from <http://www.jazindia.com/index.php/jaz/article/view/1716>
11. Mukhammadieva M. I. (2022). Modern clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis // *Texas Journal of Medical Science*. – 2022. – P. 86-90
12. Shamsiyeva, M. A. (2024). ПРОГНОСТИЧЕСКАЯ ЗНАЧЕНИЯ НЕИНВАЗИВНЫХ МЕТОДИК ДИАГНОСТИКИ ДЛЯ ОЦЕНКИ ФИБРОЗА ПЕЧЕНИ У БОЛЬНЫХ ХРОНИЧЕСКИМ ГЕПАТИТОМ С. AMALIY VA TIBBIYOT FANLARI ILMIY JURNAL, 2181-3469
13. Nabiyeva, Z. (2023). CLINICAL MANIFESTATIONS OF CHRONIC DISEASES OF ORGANS OF THE DIGESTIVE SYSTEM IN CHILDREN. *Инновационные исследования в*



современном мире: теория и практика, 2(15), 27–28. извлечено от <https://in-academy.uz/index.php/zdit/article/view/13239>

15. Mukhammadiyeva M.I. (2023). Вирус этиологияли жигар циррози беморларида спонтан бактериал перитонит билан асортатланишнинг профилактикаси ва давосини такомиллаштириш//Oriental Renaissance: Innovative, educational, natural and social sciences. - 2023.-P.947-953.

16. Oblokulov A.R., M.I. Mukhammadiyeva. (2022). Clinical and biochemical characteristics of liver cirrhosis patients of viral etiology with spontaneous bacterial peritonitis//Academicia Globe: Inderscience Research.-2022.- P. 210-216.

17. Khadiyeva Dora Isakovna. (2024). Diagnosis and Prediction of Liver Fibrosis in Chronic Viral Hepatitis C in Hiv-Infected. *International Journal of Integrative and Modern Medicine*, 2(6), 89–94. Retrieved from <https://medicaljournals.eu/index.php/IJIMM/article/view/515>

18. Shamsiyeva, M.A. (2024). Measles Infection in Pregnancy .RESEARCH JOURNAL OF TRAUMA AND DISABILITY STUDIES ,2720-6866.

19. Mukhammadiyeva Musharraf Ibrokhimovna. (2024). TREATMENT OF SPONTANEOUS BACTERIAL PERITONITIS COMPLICATED IN VIRUS ETIOLOGY LIVER CIRRHOSIS. *JOURNAL OF EDUCATION, ETHICS AND VALUE*, 3(6), 73–80. Retrieved from <https://jeev.innovascience.uz/index.php/jeev/article/view/723>

20. Sanokulova Sitara Avazovna. (2023). Factors of Development of Hepatorenal Syndrome in Patients with Liver Cirrhosis of Viral Etiology. *Texas Journal of Medical Science*, 26, 4–9. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4611>

21. Tukhtaboevna, M. Z. . (2022). ACUTE INTESTINAL INFECTIONS IN CHILDREN, MODERN PRINCIPLES OF CORRECTION AND RESTORATION OF WATER-ELECTROLYTE BALANCE. *IJTIMOIIY FANLARDA INNOVASIYA ONLAYN ILMIY JURNALI*, 101–105. Retrieved from <https://sciencebox.uz/index.php/jis/article/view/3249>

22. Shamsiyeva, M.A. (2024). Medicines for Humans, Modern Problems of Pharmacotherapy of COVID-19 in Pregnancy Women .RESEARCH JOURNAL OF TRAUMA AND DISABILITY STUDIES ,2720-6866.

23. Jalilova, A.S. (2022). THE SPREAD OF CIRRHOSIS OF THE LIVER BY ETIOLOGICAL FACTORS. *Oriental renaissance: Innovative, educational, natural and social sciences*, 2 (6), 253–257.

24. Shamsiyeva, M.A. (2024). Methods of Evaluation of Liver Cirrhosis in Hepatitis C .RESEARCH JOURNAL OF TRAUMA AND DISABILITY STUDIES ,2720-6866.

25. Облокулов, А., & Мухаммадиева, М. (2022). КЛИНИКО-ЛАБОРАТОРНАЯ ХАРАКТЕРИСТИКА СПОНТАННОГО БАКТЕРИАЛЬНОГО ПЕРИТОНИТА ПРИ ЦИРРОЗЕ ПЕЧЕНИ ВИРУСНОЙ ЭТИОЛОГИИ. Журнал вестник врача, 1(3), 66–69. извлечено от https://inlibrary.uz/index.php/doctors_herald/article/view/2016

26. Oblokulova Z.I, Oblokulov A.R, & Jalilova A.S. (2022). Diagnostic Significance of Hepatic Fibrosis in Patients with Extrahepatic Chronic Viral Hepatitis C. *Central Asian Journal of Medical and Natural Science*, 3(3), 438-443. Retrieved from <https://www.cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/806>





27. Aslonova.M.R. (2022). Determination of suicidality against the background of Parasitic Diseases in children // INTERNATIONAL JOURNAL OF PHILOSOPHICAL STUDIES AND SOCIAL SCIENCES. – 2022.- P. 9-12.
28. Jalilova, A. S. (2022). Approaches to Etiotropic Therapy of Covid-19 in Outpatient Patients. INTERNATIONAL JOURNAL OF HEALTH SYSTEMS AND MEDICAL SCIENCES, 1(1), 41-44.
29. Mukhtarova Sh.A. (2022) Age-related features of clinical manifestations of giardiasis // International journal of medical sciences and clinical research 2022;17-21.
30. Jalilova A.S. (2022). FEATURES OF CLINICAL MANIFESTATIONS OF CYTOMEGALOVIRUS INFECTION IN CHILDREN. International Journal of Medical Sciences And Clinical Research, 2(09), 12–16. <https://doi.org/10.37547/ijmscr/Volume02Issue09-04>
31. Raximovich, O. A., Sadilloevna, J. A., Abdulloyevna, M. S., & Farxodovich, R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. <https://doi.org/10.17605/OSF.IO/9CFP6>
32. Жалилова А. С. Дилноза Саётовна Косимова. Клинико–Лабораторная Характеристика Пациентов С Covid-19 И Предиктор Антибактериальной Терапии // CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES. – 2021. – С. 81-86.
33. Abdulloyevna, M. S. . (2023). Tez-Tez Kasal Bo'lgan Bolalarda O'tkir Respirator Kasalliklarning Klinik-Laboratoriya Xususiyatlari. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 29–34. Retrieved from <https://sciencebox.uz/index.php/amaltibbiyot/article/view/8680>
34. Muxtorova, S. A. (2022). Clinical and laboratoriya features of acute respiratory disease in frequently ill children. Web of scientist: International scientific research journal, 1026-1030.
35. Mukhtarova, S. H. (2022). A.(2022) AGE-RELATED FEATURES OF CLINICAL MANIFESTATIONS OF GIARDIASIS. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES AND CLINICAL RESEARCH, 17-21.
36. Mukhtarova Shokhida Abdulloevna. (2023). Microbiological Indicators of Patients Infected with SarsCov-2. Texas Journal of Medical Science, 21, 41–45. Retrieved from <https://www.zienjournals.com/index.php/tjms/article/view/4116>
37. Mukhtarova Shokhida Abdulloevna. (2023). CYTOMEGALOVIRUS INFECTIONS IN CHILDREN WITH PRIMARY AND SECONDARY IMMUNE DEFICIENCIES. Academia Science Repository, 4(06), 23–28. Retrieved from <http://academiascience.com/index.php/repo/article/view/832>
38. Aslonova.M.R. (2023). VITAMIN DEFICIENCY CASES RESULTING FROM PARASITIC DISEASES // Galaxy International Interdisciplinary Research Journal.-2023.-P. 404-409
39. Mukhtarova Shokhida Abdulloevna. (2023). CHARACTERISTIC FEATURES OF THE COURSE OF CITOMEGALOVIRUS INFECTION IN CHILDREN. Galaxy International Interdisciplinary Research Journal, 11(4), 484–487. Retrieved from <https://giirj.com/index.php/giirj/article/view/5150>.
40. Raximovich, O. A., Sadilloevna, J. A., Abdulloyevna, M. S., & Farxodovich, R. F. (2022). Microbiological Indicators of Patients with Confirmed Sars-Cov-2 - Infection. Central Asian Journal of Medical and Natural Science, 3(2), 289-294. <https://doi.org/10.17605/OSF.IO/9CFP6>





- 41.Ш. А, М. (2023). Профилактика Сезонного Распространения Орви Среди Детей Раннего Возраста. AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI, 2(12), 22–28. Retrieved from <https://www.sciencebox.uz/index.php/amaltibbiyot/article/view/8678>
- 42.М. I., М. . (2024). Features of the Clinical Course of Virus-Associated Glomerulonephritis in Children and Adolescents. *Research Journal of Trauma and Disability Studies*, 3(10), 163–169. Retrieved from <https://journals.academiczone.net/index.php/rjtds/article/view/3676>
- 43.Mukhammadieva M. I. (2024). PREVENTION OF COMPLICATIONS WITH SPONTANEOUS BACTERIAL PERITONITIS WITH LIVER CIRRHOSIS OF VIRAL ETIOLOGY. *Web of Medicine: Journal of Medicine, Practice and Nursing*, 2(12), 191–197. Retrieved from <http://webofjournals.com/index.php/5/article/view/2595>.

